Area of research
Pulmonary and Respiratory Medicine · Nephrology
Research interest
Research interests include Renal and Vascular Pathologies, Chronic Kidney Disease and Diabetes, Mesenchymal stem cell research, and Cardiovascular Disease and Adiposity.
Autophagy inhibition improves the efficacy of anlotinib and PD-1 inhibitors in the treatment of NSCLC.
S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure.
RAD54L Is a Prognostic Biomarker and Demonstrate Correlation With Drug Sensitivity in Hepatocellular Carcinoma.
Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma
The prognostic role of WeChat-based instant doctor-patient communication in patients with advanced pancreatic cancer.
POSTN Secretion by Extracellular Matrix Cancer-Associated Fibroblasts (eCAFs) Correlates with Poor ICB Response via Macrophage Chemotaxis Activation of Akt Signaling Pathway in Gastric Cancer.
Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients.
A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma.
Efficacy and safety of gemcitabine plus S-1 <i>vs.</i> gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma.
Necroptosis-related signatures identify two distinct hepatocellular carcinoma subtypes: Implications for predicting drug sensitivity and prognosis
Genomic landscape and efficacy of HER2-targeted therapy in patients with <i>HER2</i>-mutant non-small cell lung cancer.
Significance of Ultra-Radical Surgery in Extensive Metastatic Ovarian Growing Teratoma Syndrome.
Anti-PD-1 antibodies, a novel treatment option for advanced chemoresistant pulmonary lymphoepithelioma carcinoma.
Extracellular Matrix-Based Gene Expression Signature Defines Two Prognostic Subtypes of Hepatocellular Carcinoma With Different Immune Microenvironment Characteristics.
A Comprehensive Prognostic Analysis of POLD1 in Hepatocellular Carcinoma.
Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies.
Effects of Elamipretide on Autophagy in Renal Cells of Pigs with Metabolic Syndrome
Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data.
Autologous Extracellular Vesicles Attenuate Cardiac Injury in Experimental Atherosclerotic Renovascular Disease More Effectively Than Their Parent Mesenchymal Stem/Stromal Cells
Patients with non-functional metastatic G2 pancreatic neuroendocrine tumor benefit from palliative surgery: A 20-year single-center retrospective analysis.
Characteristics and Prognostic Nomogram for Primary Lung Lepidic Adenocarcinoma.
The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease.
GDI2 is a novel diagnostic and prognostic biomarker in hepatocellular carcinoma
The characteristics and nomogram for primary lung lepidic adenocarcinoma
[Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies].
Predicting Survival Outcome of Patients With Colorectal Cancer and Only Lung Metastasis: A Population-Based Real-World Study
Minichromosome maintenance 3 promotes hepatocellular carcinoma radioresistance by activating the NF-κB pathway
DDX39 promotes hepatocellular carcinoma growth and metastasis through activating Wnt/β-catenin pathway
Glomerular Hyperfiltration in Obese African American Hypertensive Patients Is Associated With Elevated Urinary Mitochondrial-DNA Copy Number
The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy